Drug Companies Failing To Provide Details on Clinical Trials, NEJM Editor Says

Main Category: Pharma Industry / Biotech Industry
Article Date: 25 May 2005 - 11:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Jeffrey Drazen, editor in chief of the New England Journal of Medicine, said on Monday that three of the largest pharmaceutical companies... -- GlaxoSmithKline, Merck and Pfizer -- are "making a mockery" of efforts to offer more transparency in clinical trials by failing to provide accurate information about their studies, the AP/Hartford Courant reports. In September 2004, the members of the International Committee of Medical Journal Editors announced that they will cease publishing studies that are not registered in an NIH database -- ClinicalTrials.gov -- at the time of their launches. The Pharmaceutical Research and Manufacturers of America and three other major pharmaceutical associations earlier this year recommended to their members that they submit clinical trial information to the public registry beginning in July. Pharmaceutical companies are legally required to register trials for products treating serious or life-threatening diseases, but in recent months they have begun registering other types of studies on the site, as well as listing them on their own Web sites. Following a review of the information posted by 10 pharmaceutical companies on the registry, Drazen said that GSK, Merck and Pfizer are failing to provide useful data on clinical trials they register on the site. Drazen said the three companies provided inadequate information on the number of patients in trials and also failed to clearly outline primary and secondary goals of the trials. Drazen said the three companies are "giving nonsense details," adding, "They are written in a way that they are trying to hide what they are doing." Drazen said that a number of other companies have complied with the requirements -- including Eli Lilly and Abbott Laboratories, which are "90% in compliance" -- but that some companies recently have begun to follow the lead of GSK, Merck and Pfizer in their disclosures (Agovino, AP/Hartford Courant, 5/24).

"Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Richard Small. "Drug Companies Failing To Provide Details on Clinical Trials, NEJM Editor Says." Medical News Today. MediLexicon, Intl., 25 May. 2005. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/25092.php>

APA
Richard Small. (2005, May 25). "Drug Companies Failing To Provide Details on Clinical Trials, NEJM Editor Says." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/25092.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »